Drug Information
| Drug General Information | |||||
|---|---|---|---|---|---|
| Drug ID |
D03FVR
|
||||
| Former ID |
DIB012008
|
||||
| Drug Name |
GSK-1827771
|
||||
| Synonyms |
IL-1 antagonist (antibody, rheumatoid arthritis), GSK
|
||||
| Drug Type |
Antibody
|
||||
| Indication | Rheumatoid arthritis [ICD9: 710-719, 714; ICD10:M05-M06] | Phase 1 | [1] | ||
| Company |
GlaxoSmithKline plc
|
||||
| Target and Pathway | |||||
| Target(s) | Interleukin-1 receptor, type II | Target Info | [2] | ||
| KEGG Pathway | MAPK signaling pathway | ||||
| Cytokine-cytokine receptor interaction | |||||
| Hematopoietic cell lineage | |||||
| Amoebiasis | |||||
| HTLV-I infection | |||||
| Transcriptional misregulation in cancer | |||||
| NetPath Pathway | IL1 Signaling Pathway | ||||
| TNFalpha Signaling Pathway | |||||
| Pathway Interaction Database | IL1-mediated signaling events | ||||
| Reactome | Interleukin-1 signaling | ||||
| WikiPathways | MAPK Signaling Pathway | ||||
| Interleukin-1 signaling | |||||
| Apoptosis Modulation and Signaling | |||||
| References | |||||
| REF 1 | ClinicalTrials.gov (NCT00539760) A Phase I Rheumatoid Arthritis Study in Healthy Volunteers. U.S. National Institutes of Health. | ||||
| REF 2 | WO patent application no. 2013,0077,63, Modulators of the nlrp3 inflammasome il-1ss pathway for the prevention and treatment of acne. | ||||
If You Find Any Error in Data or Bug in Web Service, Please Kindly Report It to Dr. Zhou and Dr. Zhang.